Therapeutic Effect of PBF-680 in Patients With COPD

Inclusion Criteria: * Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study. * Male or female aged between 40 and 80 years inclusive, at the time of informed consent. * Have a 12-lead ECG recording at screening (Visit 1) showing the following (and no changes at Visit 2 deemed clinically significant by the Investigator): Heart rate between 50 and 90 beats per minute QT interval corrected for heart rate using Fridericia's formula (QTcF) interval ≤ 450 msec for males and ≤ 470 msec for females. QRS complex ≤ 120 msec PR interval ≤ 200 msec * No clinically significant abnormality including morphology (e.g. left bundle branch block, atrioventricular nodal dysfunction, ST segment abnormality consistent with ischemia). * Capable of complying with all study restrictions and procedures. * Body mass index (BMI) between 20 and 35 kg/m2 (inclusive) * COPD diagnosis: Patients with a clinical diagnosis of COPD as defined by Global Initiative for Chronic Obstructive Lung Disease - GOLD 20201 with symptoms compatible with COPD for at least 1 year prior to screening (Visit 1). * Background triple therapy (ICS + LABA + LAMA) or double therapy (ICS + LABA or ICS + LAMA) for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to Visit 1. * Patient with blood eosinophils \>100 cells/µL * Ability to perform acceptable and reproducible spirometry. Post- bronchodilator (albuterol/salbutamol four puffs) spirometry at screening (Visit 1) must demonstrate a: Post-bronchodilator FEV1/FVC ratio ≤ 0.70 Post-bronchodilator FEV1 ≥ 30 % and: ≤ 75 % of predicted normal. * Clinically stable COPD in the 4 weeks prior to screening (Visit 1) and randomization (Visit 2). * Meet the concomitant medication restrictions and be expected to do so for the rest of the study. * Current and former smokers with a smoking history of ≥ 10 pack years. Exclusion Criteria: * Participants who have not been Vaccinated against SARS-CoV-2 and after performing a diagnostic nucleic acid test at screening visit, this would produce a positive result * Participants with a significant COVID-19 illness ≥ OMS-4 within 6 months of enrolment * A history of life-threatening COPD including Intensive Care Unit admission and requiring intubation. * COPD exacerbation requiring oral steroids in the 3 months prior to randomization (Visit 2). * A history of one or more hospitalizations for COPD in the 3 months prior to screening (Visit 1). * Lower respiratory tract infection treated with antibiotics within 1 months of randomization (Visit 2). * Increased pre-BD FEV1 at randomization visit (V2) compared to Screening (V1) of ≥ 400 mL or ≥ 20% of V1 FEV1. * Evidence of cor pulmonale or clinically significant pulmonary hypertension. * Other respiratory disorders: Patients with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, known alpha-1 antitrypsin deficiency or other active pulmonary diseases. * Previous lung resection or lung reduction surgery. * Oral therapies for COPD (e.g., theophylline, and roflumilast) in 1 month prior to screening (Visit 1) and throughout the study. * Pulmonary rehabilitation, unless such treatment has been stable for 4 weeks prior to Visit 1) and remains stable during the trial. * A history of, or reason to believe a subject has, drug or alcohol abuse within the past 3 years. * Received an experimental drug within 30 days or five half-lives of Visit 2, whichever is longer. * Women who are pregnant or breast-feeding. * Patients with a history of chronic uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, or ophthalmic diseases that the Investigator believes are clinically significant. * Documented cardiovascular disease: arrhythmias, unstable angina, recent or suspected myocardial infarction within 6 months prior to screening, congestive heart failure, a history of unstable or uncontrolled hypertension, or has been diagnosed with hypertension in last 3 months.